309 related articles for article (PubMed ID: 38263193)
1. Inhibitor of PD-1/PD-L1: a new approach may be beneficial for the treatment of idiopathic pulmonary fibrosis.
Tan J; Xue Q; Hu X; Yang J
J Transl Med; 2024 Jan; 22(1):95. PubMed ID: 38263193
[TBL] [Abstract][Full Text] [Related]
2. The role of PD-1/PD-L1 axis in idiopathic pulmonary fibrosis: Friend or foe?
Jiang A; Liu N; Wang J; Zheng X; Ren M; Zhang W; Yao Y
Front Immunol; 2022; 13():1022228. PubMed ID: 36544757
[TBL] [Abstract][Full Text] [Related]
3. Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis.
Karampitsakos T; Galaris A; Chrysikos S; Papaioannou O; Vamvakaris I; Barbayianni I; Kanellopoulou P; Grammenoudi S; Anagnostopoulos N; Stratakos G; Katsaras M; Sampsonas F; Dimakou K; Manali ED; Papiris S; Tourki B; Juan-Guardela BM; Bakakos P; Bouros D; Herazo-Maya JD; Aidinis V; Tzouvelekis A
Respir Res; 2023 Nov; 24(1):279. PubMed ID: 37964265
[TBL] [Abstract][Full Text] [Related]
4. IL-8 concurrently promotes idiopathic pulmonary fibrosis mesenchymal progenitor cell senescence and PD-L1 expression enabling escape from immune cell surveillance.
Yang L; Xia H; Gilbertsen A; Smith K; Racila E; Bitterman PB; Henke CA
Am J Physiol Lung Cell Mol Physiol; 2023 Jun; 324(6):L849-L862. PubMed ID: 37121574
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis?
Duitman J; van den Ende T; Spek CA
J Clin Med; 2019 Sep; 8(10):. PubMed ID: 31561518
[TBL] [Abstract][Full Text] [Related]
6. Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice.
Qin W; Zou J; Huang Y; Liu C; Kang Y; Han H; Tang Y; Li L; Liu B; Zhao W; Yuan X
Oncoimmunology; 2020 Sep; 9(1):1824631. PubMed ID: 33457101
[TBL] [Abstract][Full Text] [Related]
7. Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells.
Tu J; Xu H; Ma L; Li C; Qin W; Chen X; Yi M; Sun L; Liu B; Yuan X
Theranostics; 2022; 12(2):747-766. PubMed ID: 34976211
[No Abstract] [Full Text] [Related]
8. Regulatory Effect of PD1/PD-Ligand 1 (PD-L1) on Treg Cells in Patients with Idiopathic Pulmonary Fibrosis.
Wang B; Bai W; Ma H; Li F
Med Sci Monit; 2021 Jan; 27():e927577. PubMed ID: 33386384
[TBL] [Abstract][Full Text] [Related]
9. Idiopathic pulmonary fibrosis: Current and future treatment.
Glass DS; Grossfeld D; Renna HA; Agarwala P; Spiegler P; DeLeon J; Reiss AB
Clin Respir J; 2022 Feb; 16(2):84-96. PubMed ID: 35001525
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 upregulation promotes drug-induced pulmonary fibrosis by inhibiting vimentin degradation.
Li Q; Deng MS; Wang RT; Luo H; Luo YY; Zhang DD; Chen KJ; Cao XF; Yang GM; Zhao TM; Xu B; Xu CX; Wang JM
Pharmacol Res; 2023 Jan; 187():106636. PubMed ID: 36586643
[TBL] [Abstract][Full Text] [Related]
11. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
Feng H; Zhao Y; Li Z; Kang J
Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
[TBL] [Abstract][Full Text] [Related]
13. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 on invasive fibroblasts drives fibrosis in a humanized model of idiopathic pulmonary fibrosis.
Geng Y; Liu X; Liang J; Habiel DM; Kulur V; Coelho AL; Deng N; Xie T; Wang Y; Liu N; Huang G; Kurkciyan A; Liu Z; Tang J; Hogaboam CM; Jiang D; Noble PW
JCI Insight; 2019 Mar; 4(6):. PubMed ID: 30763282
[TBL] [Abstract][Full Text] [Related]
15. PD-1/PD-L1 inhibitor ameliorates silica-induced pulmonary fibrosis by maintaining systemic immune homeostasis.
Zhao Y; Hao C; Li M; Qu Y; Guo Y; Deng X; Si H; Yao W
Biomed Pharmacother; 2022 Apr; 148():112768. PubMed ID: 35247717
[TBL] [Abstract][Full Text] [Related]
16. Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis-a pilot study.
Jovanovic D; Roksandic Milenkovic M; Kotur Stevuljevic J; Markovic J; Ceriman V; Kontic M; Skodric Trifunovic V
J Thorac Dis; 2018 Dec; 10(12):6660-6669. PubMed ID: 30746211
[TBL] [Abstract][Full Text] [Related]
17. Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib.
Bonella F; Stowasser S; Wollin L
Drug Des Devel Ther; 2015; 9():6407-19. PubMed ID: 26715838
[TBL] [Abstract][Full Text] [Related]
18. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners.
Wojtukiewicz MZ; Rek MM; Karpowicz K; Górska M; Polityńska B; Wojtukiewicz AM; Moniuszko M; Radziwon P; Tucker SC; Honn KV
Cancer Metastasis Rev; 2021 Sep; 40(3):949-982. PubMed ID: 34236546
[TBL] [Abstract][Full Text] [Related]
20. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
